Preclinical Testing of CAR T Cells in a Patient-Derived Xenograft Model of Glioblastoma Journal Articles uri icon

  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All


  • Glioblastoma (GBM) is the most common malignant adult brain tumor that is resistant to the standard care therapy. Advances in chimeric antigen receptor (CAR) T cell therapies have spurred renewed interest in developing CAR T cell therapies to target chemoradiotherapy-resistant brain tumor-initiating cells. This protocol shows how to isolate peripheral blood mononuclear cells from healthy donors and generate CAR T cells for the antigens of interest, and how to intracranially inject the CAR T cells into a patient-derived xenograft mouse model of GBM. For complete details on the use and execution of this protocol, please refer to Vora et al. (2020).


  • Tatari, Nazanin
  • Maich, William T
  • Salim, Sabra K
  • Mckenna, Dillon
  • Venugopal, Chitra
  • Singh, Sheila

publication date

  • December 2020